Abstract LBA14
Background
We aimed to assess the role of genomic HLA-I/II heterozygosity in the overall survival benefit in patients with unresectable locally advanced, metastatic non-small lung cancer treated by PD1/L1 inhibitors.
Methods
We collected blood from 170 advanced lung cancer patients treated with immunotherapy at two major oncology centres in Western Australia. High quality DNA was extracted from white blood cells and used for HLA-I/II typing. Information of tumour PDL1 status, pre-treatment neutrophil to lymphocyte ratio (NLR) and sex were identified. Each of those variables were correlated independently then in a multivariate analysis with OS. Correlation between HLA heterozygosity and response was assessed using Fisher exact. Patients with reduced or stable disease for 6 or more months were considered as responders.
Results
Our data matured for 146 patients treated with anti-PD1/L1 therapy. We found that heterozygosity at all HLA-I loci had a favorable statistical trend towards better OS(HR = 0.5,P=0.06). However, heterozygosity at all HLA-II loci was not associated with OS(HR = 0.91,P=0.76). While response rate was higher amongst heterozygous patients especially at HLA-I (53.4% vs 45.6%), it was not statistically significant. NLR>5 was associated with statistically significant worse survival (HR = 2.22,P=0.009). This effect was driven by the patients with PDL1≥50% (HR = 3.86, P = 0.01 vs HR = 0.7, P = 0.5 for patients with PDL1<50%). Similarly, the effect of sex was seen mainly among patients with PDL1≥50%, with men more likely to have better OS than women (HR = 0.36, P = 0.06 vs HR = 1.1, P = 0.89 in the group of patients with PDL1<50%). A multivariate analysis showed that all three variables to be statistically significant predictors of survival.
Table: LBA14
Variable | HR(95% CI) | P value |
---|---|---|
Sex | 1.9(1.1-3.5) | 0.028 |
NRLD(≥5vs<5) | 7.1(1.8-27.3) | 0.004 |
Homozygosity at ≥ 1 HLA-I | 0.3(0.8-0.9) | 0.039 |
Conclusions
Our analysis suggest that OS among advanced lung cancer patients treated with immunotherapy is more likely to be influenced by homozygosity at HLA-I loci. Women with PDL1≥50%, NLR>5 and homozygous at ≥ 1 HLA-I locus possibly carries the worse prognosis when treated with immunotherapy alone and might benefit from treatment escalation.
Clinical trial identification
Editorial acknowledgement
A/Prof Elin Gray, Edith Cowan University, Western Australia.
Legal entity responsible for the study
South Metropolitan Health Service - WA Health.
Funding
Fiona Stanley Hospital (FSH) and Sir Charles Gairdner Hospital (SCGH)
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Association of survival and blood-based genomic signature with atezolizumab for patients with second-line and third-line EGFR wild-type non-small cell lung cancer: Pooled analysis of individual patient data from the POPLAR and OAK trials
Presenter: Yunfang Yu
Session: Mini Oral session - Immunotherapy of cancer
Resources:
Slides
Webcast
318O - Both low and high blood tumour mutational burden are favourable predictors with atezolizumab
Presenter: Wei Nie
Session: Mini Oral session - Immunotherapy of cancer
Resources:
Abstract
Combined model of frameshift mutations and TMB in predicting response to immunotherapy in NSCLC
Presenter: Huaqiang Zhou
Session: Mini Oral session - Immunotherapy of cancer
Resources:
Slides
Webcast
PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in NSCLC
Presenter: Jiaqing Liu
Session: Mini Oral session - Immunotherapy of cancer
Resources:
Slides
Webcast
Data-driven miRNA classifier as response predictor for immune checkpoint inhibitor treatment in advanced-stage cancer patients
Presenter: Chia-Hsun Hsieh
Session: Mini Oral session - Immunotherapy of cancer
Resources:
Slides
Webcast